For research use only
| Cat No. | ABC-X0025C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
This engineered BAF3 cell line expresses ETV6-FGFR4 (C477S) to investigate oncogenic kinase signaling and response to therapeutic inhibitors.
The ETV6 FGFR4 (C477S) BAF3 Cell Line is engineered by lentiviral transduction of human ETV6-FGFR4 fusion carrying the C477S mutation into BAF3 cells. This alteration disrupts native disulfide bonding, mimicking ligand-independent receptor dimerization and activation.
Target
FGFR4 mutations at C477 are known to stabilize kinase activation. The ETV6-FGFR4 (C477S) fusion promotes oncogenic signaling, contributing to cell survival and proliferation in hematologic disorders. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0025C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This cell line enables assessment of FGFR4-targeted inhibitors and downstream oncogenic signaling, offering a reliable model for precision therapy research.